Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Neurologic disorders in long-term survivors of neuroblastoma - a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Improved Survival of Children, Adolescents, and Young Adults With Head and Neck Soft Tissue Sarcomas in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Filippa Nyboe Norsker
  • Catherine Rechnitzer
  • Elisabeth Wreford Andersen
  • Karen Markussen Linnet
  • Line Kenborg
  • Anna Sällfors Holmqvist
  • Laufey Tryggvadottir
  • Laura-Maria Madanat-Harjuoja
  • Ingrid Øra
  • Halldora K Thorarinsdottir
  • Kim Vettenranta
  • Andrea Bautz
  • Henrik Schrøder
  • Henrik Hasle
  • Jeanette Falck Winther
View graph of relations

Background: Neuroblastoma is the commonest extracranial solid tumor of childhood, yet rare, and with poor survival before 1990, especially for high-risk disease; thus, information on late effects is sparse. With great advances in cancer treatment, survival has reached 80% in the Nordic countries. The aim of the study was to investigate the risk of developing neurologic disorders after neuroblastoma. Material and methods: Through population-based cancer registries of four Nordic countries we identified 654 5-year survivors of neuroblastoma (diagnosed 1959-2008) and 133,668 matched population comparisons. We grouped neurologic diagnoses from national hospital registries into 11 main diagnostic categories and 56 disease-specific sub-categories and calculated relative risks (RRs), absolute excess risks (AERs), cumulative incidence and mean cumulative count (MCC). Information on cancer treatment was available for 49% of survivors. Results: A hospital contact for a neurologic disorder was observed in 181 survivors 5 years or more from cancer diagnosis with 59 expected, yielding a RR of 3.1 (95% CI 2.7-3.6) and an AER of 16 per 1,000 person-years (95% CI 12-19). The most frequent disorders included epilepsy, paralytic syndromes, diseases of the eyes and ears and hearing loss. The cumulative incidence of any neurologic disorder was 31% in survivors 20 years after cancer diagnosis with a MCC of 0.5 unique diagnoses. All risks were highest in survivors of high-risk neuroblastoma. Conclusion: Neuroblastoma survivors represent a population with a high risk of developing neurologic disorders. Our results should contribute to improving health care planning and underscores the need for systematic follow-up care of this vulnerable group of survivors.

Original languageEnglish
JournalActa oncologica
Issue number2
Pages (from-to)134-140
Number of pages7
Publication statusPublished - Feb 2020

ID: 59232318